stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Revenue growth
Spyre Therapeutics, Inc.'s revenue growth over the twelve months to 31 December 2023 was −81.8%. Over the past ten years it has ranged from −87.6% (fiscal 2022) to 382.0% (fiscal 2021); the current reading is higher than 29% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2023 | −62.0% | 25.61 |
| FY2022 | −87.6% | (469.54) |
| FY2021 | 382.0% | 407.27 |
| FY2018 | −25.3% | (37.77) |
| FY2017 | 12.5% | 36.41 |
| FY2016 | −23.9% | (55.42) |
| FY2015 | 31.5% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Dec 2023 | −100.0% | (110.08) |
| Jun 2023 | 10.1% | 95.54 |
| Mar 2023 | −85.5% | 9.93 |
| Dec 2022 | −95.4% | (7.83) |
| 19 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| IBRX ImmunityBio, Inc. compare | 192.9% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 92.8% |
| TGTX TG Therapeutics, Inc. compare | 76.1% |
| CAI Caris Life Sciences,�Inc. compare | 68.8% |
| PTGX Protagonist Therapeutics, Inc. compare | 34.8% |
| CYTK Cytokinetics, Incorporated compare | 29.9% |
| KRYS Krystal Biotech, Inc. compare | 26.0% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| SYRE Spyre Therapeutics, Inc. | −81.8% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement